NextPharma Acquires Chewable Tablets Manufacturing Site in Norway

Published on: 

NextPharma has acquired a leading European chewable tablets manufacturing site from Takeda in Asker, Norway.

NextPharma, a European contract development and manufacturing organization (CDMO), announced on April 1, 2023 that it has acquired a leading chewable tablets manufacturing site from Takeda located in Asker, Norway.

The site, which has approximately 170 employees, has operated for more than 50 years and produces a broad portfolio of strengths and flavors of calcium/vitamin D3 chewable tablets. The site will be NextPharma’s center of excellence for the development and manufacturing of chewable tablet forms, adding to the company’s existing site portfolio.

“With NextPharma, we are confident that Takeda has chosen a buyer who will help nurture and grow the Asker site,” said Bjørn Lie, head of the manufacturing site at Asker, in a company press release. “We are all excited about joining the NextPharma team and look forward to working together to drive the long-term development and growth of the business and our people.”


“We are excited by the addition of a world-class manufacturing site and a new center of excellence for chewable tablets to our operational network, allowing us to further broaden our technology offering for both existing and new customers,” added Peter Burema, CEO of NextPharma, in the release. “These technologies, combined with the know-how and expertise of the site’s employees, will continue to benefit patients across the world.”
Source: NextPharma